Use of non steroidal aromatase inhibitors in treatment of patients with early invasive hormone-dependent breast cancer in everyday clinical practice

Submission date	Recruitment status	Prospectively registered
26/04/2011	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
06/06/2011	Completed	Results
Last Edited	Condition category	Individual participant data
06/06/2011	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Eduard Vrdoljak

Contact details

Clinical Hospital Center Split Split Croatia 21000

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ANA-2010/01-HR

Study information

Scientific Title

Use of non steroidal aromatase inhibitors in treatment of patients with early invasive hormonedependent breast cancer in everyday clinical practice: non-interventional, multicentre study

Study objectives

The main aim is to assess patients compliance to non steroidal aromatase inhibitors. The patients will be considered compliant if they take > 80% of medication. According to published data it is expected that patients who have been receiving aromatase inhibitors (AI) therapy for longer period of time (i.e. for 3 years at the beginning of this non-interventional study) will be less compliant than those who have been started with the therapy recently. In addition it is expected that approximately 20% of all included patients will be non-compliant which allows us to analyse influence of socioeconomic parameters on non-compliance (which is one of our secondary objectives).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central Ethics Committee, Croatia approved on 23rd March 2011

Study design

Non-interventional multicentre study

Primary study design

Observational

Secondary study design

Non randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Early invasive hormone-dependent breast cancer

Interventions

Patients on non steroidal aromatase inhibitors will come for 6 visits: baseline, after 2, 6, 12, 18 and 24 months - which reflects standard practice in Croatia. Only clinical examination and those diagnostic methods which are part of standard clinical practice in Croatia will be performed. Investigators will record in patients case report form (CRF) which methods have been performed at each visit. In case of disease progression, patient will end the study.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Non steroidal aromatase inhibitors

Primary outcome measure

Patients' compliance to non steroidal aromatase inhibitors therapy in everyday clinical practice in Croatia. Patient will be given diary in which she will assess how many doses she has missed each month. This will be checked by the Investigator at each visit. In addition, if patients is not taking the medication regularly, the Investigator will record the reason [i.e. adverse drug reactions (ADR), forgetting to take medication, etc]

Secondary outcome measures

- 1. Patients compliance to therapy for prevention and/or treatment of osteoporosis (if any prescribed)
- 2. Influence of socioeconomic parameters on patients compliance
- 3. Effectiveness of non-steroidal inhibitors in everyday clinical practice in Croatia (progression free survival, time to progression, overall survival)
- 4. Safety of non steroidal aromatse inhibitors

Overall study start date

27/04/2011

Completion date

31/12/2013

Eligibility

Key inclusion criteria

- 1. Patients with early invasive breast cancer
- 2. Hormone-dependent disease
- 3. Postmenopausal women
- 4. Eastern Cooperative Oncology Group (ECOG) 0-1
- 5. Signed informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

500

Key exclusion criteria

- 1. Metastatic breast cancer
- 2. Premenopausal women
- 3. Pregnancy or lactation
- 4. Patients with severe renal impairment
- 5. Patients with moderate to severe hepatic disease
- 6. Known hypersensitivity to anastrozole or letrozole or any of the excipients
- 7. Concurrent oestrogen containing therapy
- 8. Concurrent tamoxifen therapy
- 9. Previous treatment with tamoxifen
- 10. Previous treatment with any other aromatase inhibitor

Date of first enrolment

27/04/2011

Date of final enrolment

31/12/2013

Locations

Countries of recruitment

Croatia

Study participating centre Clinical Hospital Center Split

Split Croatia

21000

Sponsor information

Organisation

PLIVA Croatia Ltd. (Croatia)

Sponsor details

Prilaz baruna Filipovic 25 Zagreb Croatia 10000

Sponsor type

Industry

ROR

https://ror.org/02cthxa95

Funder(s)

Funder type Industry

Funder Name PLIVA Croatia Ltd. (Croatia)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration